GxP Insights: Capital vs. Capability: Nicholas Bonavita on Getting a $30 Million Sterile Manufacturing Expansion Off the Ground

8 mins

With a career built across some of the most demanding environments in life sciences manufact...

By Harry Reeve

Principal Consultant

With a career built across some of the most demanding environments in life sciences manufacturing, Operations and Engineering Leader Nicholas Bonavita has led capital programs ranging from tens of millions to well over a billion dollars in scope. In this edition of GxP Insights, i-Pharm GxP's Harry Reeve sits down with him to focus on one of them: a $30 million capital expansion at a specialist CDMO, and what it takes to step into a program of that scale and get it moving.

In keeping with i-Pharm GxP's commitment to client confidentiality, the companies and sites featured in GxP Insights are not named.



When Nick Bonavita came into this program, one of the first things he had to do was get a clear picture of where things stood. Firstly, what the business ultimately wanted. Secondly, what had already been contracted. And thirdly, what was actually required to bring the new capability online. Three things that didn't yet tell a single coherent story.

"The most interesting challenge was translating the business's ambition into an accurate technical plan.”

His job wasn't simply to point out the gaps. It was to turn them into decisions and actions that would bring value to the business.

“Do we adjust scope? Do we add investment? Do we change the resourcing? And bringing those decisions very clearly to the stakeholders, to the core team, and to ownership, so that we can make informed decisions instead of discovering those later."

What makes Nick the right person for a program like this starts well before this engagement. So, let’s take a look at his background first.



The Career Behind the Role

Nick Bonavita is an Operations and Engineering Leader specializing in manufacturing, tech transfer, and GMP, with a track record of building new capabilities and scaling existing pharmaceutical production. His career has taken him across some of the most complex regulated environments in the life sciences industry.

He’s led operations for a $2 billion sterile injectables facility at a global pharmaceutical manufacturer through its initial start-up. More recently, he stood up operations for a viral vector and cell and gene therapy site as it moved toward commercial launch. In between, he directed global technology transfer programs into and across sites in the U.S., Australia, Europe, and Asia, and before that, he led capital projects ranging from the tens of millions to well over a billion dollars in scope.

"That progression has shaped how I look at capital programs. It's not just about the equipment or the facility milestone. It's really answering the question: if operations can run the process, can quality release it? And ultimately, will it deliver the capability the business was purchasing?"


Inside the Program

The program we're focusing on in this edition is a $30 million capital expansion Nick took on at a specialist CDMO: a new end-to-end filling line that would expand the organization's sterile manufacturing capability and give the business additional capacity to support current and future clients. A significant step in the business' growth journey.

What does that mean in plain English?

A filling line is the core of sterile pharmaceutical manufacturing, the equipment and surrounding systems that fill, seal, and prepare drug products for patients. Getting a new line from equipment delivery to GMP-ready manufacturing capability requires not just the equipment itself, but the facilities, utilities, automation, qualification, and all of the capability development and training needed to make it productive. When one flaw or one error can mean millions of dollars of product loss, the margin for getting it wrong is effectively zero.

Nick came into the program after the major equipment had already been procured. His mandate was to integrate everything around that investment and create a credible path to operational readiness.

"Buying the process equipment and delivering the business capability are not the same thing. The equipment is one part of a much larger system. My role was to bring those pieces together into one scope, one integrated schedule, and ultimately one view of what it's going to take to deliver that for the business."

One of the first things he had to address was pace. The organization wanted to move quickly, which meant a significant part of his early work was identifying where the program could be intelligently accelerated, and where pushing harder would simply transfer risk downstream.

"An aggressive schedule is useful. An unrealistic one is not."


The Cultural Shift

For a project of this size at an organization growing into it, the technical challenge was only part of the picture. The bigger task was making sure the site felt like it was part of the program, not just watching it unfold.

"What matters most is establishing relationships very early, understanding who the real stakeholders are and building a governance structure with clear roles and accountability across that structure. You want genuine engagement across the team, not just compliance. You want the site to feel like it's part of the journey rather than watching it happen."

That meant shifting the framing deliberately: not engineering delivering a machine, but the business growing to serve more clients.

"That's been a cultural shift, not just a technical one. Once you have that alignment and that engagement, there's a shared language in place. The pressure shifts from being just one person trying to deliver this to the whole team carrying it together, finding the solutions and uncovering the risks early so that we can make the adjustments that are needed."


Remote Leadership

Nick managed most of this work remotely. For a program at this scale, at a site he hadn't worked with before, that required a specific approach.

"Remote leadership only works if you've invested time into the relationships first. For me, that means going and meeting the team in person early, which is non-negotiable. I wanted to understand who is at the site, who they are, their backgrounds, what pressure they're feeling, but also how they prefer to work."

After that foundation is in place, remote execution becomes much easier. But presence, Nick said, is not about being at every meeting.

"For me, it's being prepared, being responsive, having the one-on-ones, having the time to talk through challenges with the team and find where they're coming from. And making sure that the time I'm asking from the team is valuable and that I'm prepared for it."


Getting It Right From Day One

When asked what contractors need to get right from the start of a program like this, and what companies need to have in place, Nick was clear on the answer.

"One of the most expensive mistakes in capital projects is confusing the equipment delivery with the operational delivery. Purchasing the equipment and the timeline and cost to make that happen is very easy to understand. But what's less visible early on is everything required to make that equipment and the facilities productive: the facility modifications, the utilities, the automation, but also developing the capability of the team."

The strongest organizations, he said, invest appropriately in early phase design before locking in their final cost and schedule. On this particular program, that meant going back to establish the foundation and governance, identifying where things stood, what needed to keep moving, and what needed to be adjusted to account for everything on the end-to-end spectrum. Nick’s takeaway?

"Good front-end planning doesn't slow the project down. It prevents a project from discovering its scope while it's trying to execute it."


Beyond the Program

Harry asked Nick what aspect of his role he enjoys most:

"I won't say it's one particular aspect. It's really being at the crossroads of a couple: the technology, the people, and the purpose."

On the technology side, Nick genuinely loves seeing the solutions vendors are developing to address new technical challenges. Another part that has stood out is the people: meeting new people from different backgrounds at the site, internationally, and across the vendors and teams supporting the program.

"But what's kept me in life sciences is that we're not just building a facility and bringing on new technology for the sake of it. We’re building a capability to produce medicines that make a difference in patients' lives. The satisfaction is when you move from drawings and schedules to a functional operation, with a team that's confident and delivering real value to the community."


The Move to Contracting

Nick has spent most of his career on the permanent side, often in large operational leadership roles. What brought him to contracting was a combination of factors:

"What appealed to me about consulting was the opportunity to find a program that allowed me to focus intensely on the kind of work I've always enjoyed: complex technical programs, manufacturing strategy, bringing on new capability. The flexibility mattered to me as well. I wanted to be deliberate about where I spend my time, both professionally and personally."

On whether contracting felt different from permanent employment: not particularly. Nick approached it the way he would any other role.

His advice to others in a similar position, senior professionals who get approached about contract opportunities:

"You have to build the foundation first and understand what your own personal and professional goals are. Then be disciplined about which opportunities you're saying yes to. Don't chase the roles. Chase the specific expertise you want and what will ultimately fulfil the goals you set for yourself."


The Market

U.S. life sciences manufacturing is in the middle of its biggest expansion in a generation. Harry asked Nick what that means for the kind of work he does, and what companies need to do to be ready.

"The capital alone doesn't build the capability. Companies are going to need folks who can connect those disciplines. Operations has to be able to run the technical solution. The validation strategy needs to work for the schedule, not against it. Automation is becoming the driver for quality and supply chain efficiencies. Companies are going to be looking for SMEs who know how to integrate all of those pieces together to make those investments productive."

And for professionals wondering how to get onto those programs:

"Reach out to your contacts. You will be very surprised to see how many opportunities are out there that you may not find if you are looking, or even if you're just curious. The question never hurts."

About

Harry Reeve is a Principal Consultant at i-Pharm GxP, specializing in connecting senior professionals with Statement-of-Work (SOW) consulting engagements across major life sciences manufacturing programs in the United States. GxP Insights is our monthly interview series, giving you a look behind the scenes of the programs shaping the future of the industry. Subscribe so you don't miss the next one.

Interested in SOW consulting in life sciences manufacturing? Join the i-Pharm GxP network and we'll reach out when the right program comes up.


Found these insights helpful? Be sure to share them with your network and subscribe here for monthly updates and exclusive industry insights straight to your Inbox.